(SeaPRwire) – SAN DIEGO and SUZHOU, China, March 17, 2026 — Adagene Inc. (“Adagene” or the Company) (Nasdaq: ADAG), a firm focused on revolutionizing the discovery and development of new antibody-based treatments, today shared that muzastotug will be featured in two poster presentations at this year’s AACR Meeting, held April 17–22 in San Diego, CA.
The following abstracts have been chosen for presentation at AACR 2026:
Title: Phase 1b assessment of ADG126 (muzastotug, an anti-CTLA-4 masking antibody) plus pembrolizumab (Pembro) IO doublet combined with fruquintinib (Fruq) in advanced and metastatic microsatellite stable colorectal cancer
Session Title: Phase I Clinical Trials in Progress
Session Start: April 20, 2026, 9:00 AM – 12:00 PM Pacific Time
Location: Poster Section 51
Poster Board Number: 14
Abstract Presentation Number: CT083
Title: Findings from the Phase 1b/2 Morpheus Liver study in patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC): Muzastotug (ADG126: masked anti-CTLA-4 antibody) combination cohort
Session Title: First-in-Human Phase I Clinical Trials
Session Start: April 20, 2026, 9:00 AM – 12:00 PM Pacific Time
Location: Poster Section 50
Poster Board Number: 14
Abstract Presentation Number: CT054
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotech company dedicated to transforming the discovery and development of new antibody-based cancer immunotherapies. Adagene merges computational biology and artificial intelligence to create novel antibodies that meet unmet patient needs worldwide. The firm has established strategic partnerships with leading global entities that utilize its SAFEbody precision masking technology in cutting-edge scientific approaches.
Backed by its proprietary Dynamic Precision Library (DPL) platform—made up of NEObody™, SAFEbody, and POWERbody™ technologies—Adagene’s highly distinct pipeline includes innovative immunotherapy programs. The company’s SAFEbody technology is engineered to tackle safety and tolerability issues linked to many antibody treatments by using precision masking to protect the biologic therapy’s binding domain. Activated in the tumor microenvironment, this enables tumor-specific antibody targeting while reducing on-target, off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, muzastotug (ADG126), is a masked anti-CTLA-4 SAFEbody with FDA Fast Track status that targets a unique CTLA-4 epitope in regulatory T cells (Tregs) within the tumor microenvironment. Muzastotug is currently in Phase 1b/2 and Phase 2 trials in combination with anti-PD-1 therapy, with a focus on microsatellite stable (MSS) metastatic colorectal cancer (CRC). Supported by ongoing clinical research, the SAFEbody platform can be used for various antibody-based therapeutic formats, including Fc-enhanced antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers.
For additional information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn, and X.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Investor Contacts:
Raymond Tam
raymond_tam@adagene.com
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content.
Category: Top News, Daily News
SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.